Question: What is the brand name of the injectable drug for type 2 diabetes that was marketed by a Danish multinational pharmaceutical company with a majority shareholder Novo Holdings A/S?
Sentence (from "Liraglutide"): Liraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.
Relevant evidence: No